Xin Mei1, Yin-Sheng Chen1, Fu-Rong Chen1, Shao-Yan Xi1, Zhong-Ping Chen1. 1. Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Abstract
BACKGROUND: Glioblastoma cell-initiated vascularization is an alternative angiogenesis called vasculogenic mimicry. However, current knowledge on the mechanism of de novo vessel formation from glioblastoma stem cells (GSCs) is limited. METHODS: Sixty-four glioblastoma samples from patients and 10 fluorescent glioma xenograft samples were examined by immunofluorescence staining for endothelial marker (CD34 and CD31) and glial cell marker (glial fibrillary acidic protein [GFAP]) expression. GSCs were then isolated from human glioblastoma tissue and CD133+/Sox2+ red fluorescent protein-containing (RFP)-GSC-1 cells were established. The ability of these cells to form vascular structures was examined by live-cell imaging of 3D cultures. RESULTS: CD34-GFAP or CD31-GFAP coexpressing glioblastoma-derived endothelial cells (GDEC) were found in 30 of 64 (46.9%) of clinical glioblastoma samples. In those 30 samples, GDEC were found to form vessel structures in 21 (70%) samples. Among 21 samples with GDEC vessels, the CD34+ GDEC vessels and CD31+ GDEC vessels accounted for about 14.16% and 18.08% of total vessels, respectively. In the xenograft samples, CD34+ GDEC were found in 7 out of 10 mice, and 4 out of 7 mice had CD34+ GDEC vessels. CD31+ GDEC were also found in 7 mice, and 4 mice had CD31+ GDEC vessels (10 mice in total). Through live-cell imaging, we observed gradual CD34 expression when cultured with vascular endothelial growth factor in some glioma cells, and a dynamic increase in endothelial marker expression in RFP-GSC-1 in vitro was recorded. Cells expressed CD34 (9.46%) after 6 hours in culture. CONCLUSIONS: The results demonstrated that GSCs may differentiate into endothelial cells and promote angiogenesis in glioblastomas.
BACKGROUND: Glioblastoma cell-initiated vascularization is an alternative angiogenesis called vasculogenic mimicry. However, current knowledge on the mechanism of de novo vessel formation from glioblastoma stem cells (GSCs) is limited. METHODS: Sixty-four glioblastoma samples from patients and 10 fluorescent glioma xenograft samples were examined by immunofluorescence staining for endothelial marker (CD34 and CD31) and glial cell marker (glial fibrillary acidic protein [GFAP]) expression. GSCs were then isolated from human glioblastoma tissue and CD133+/Sox2+ red fluorescent protein-containing (RFP)-GSC-1 cells were established. The ability of these cells to form vascular structures was examined by live-cell imaging of 3D cultures. RESULTS: CD34-GFAP or CD31-GFAP coexpressing glioblastoma-derived endothelial cells (GDEC) were found in 30 of 64 (46.9%) of clinical glioblastoma samples. In those 30 samples, GDEC were found to form vessel structures in 21 (70%) samples. Among 21 samples with GDEC vessels, the CD34+ GDEC vessels and CD31+ GDEC vessels accounted for about 14.16% and 18.08% of total vessels, respectively. In the xenograft samples, CD34+ GDEC were found in 7 out of 10 mice, and 4 out of 7 mice had CD34+ GDEC vessels. CD31+ GDEC were also found in 7 mice, and 4 mice had CD31+ GDEC vessels (10 mice in total). Through live-cell imaging, we observed gradual CD34 expression when cultured with vascular endothelial growth factor in some glioma cells, and a dynamic increase in endothelial marker expression in RFP-GSC-1 in vitro was recorded. Cells expressed CD34 (9.46%) after 6 hours in culture. CONCLUSIONS: The results demonstrated that GSCs may differentiate into endothelial cells and promote angiogenesis in glioblastomas.
Authors: Laila Ritsma; Saskia I J Ellenbroek; Anoek Zomer; Hugo J Snippert; Frederic J de Sauvage; Benjamin D Simons; Hans Clevers; Jacco van Rheenen Journal: Nature Date: 2014-02-16 Impact factor: 49.962
Authors: Huaming Yan; Mónica Romero-López; Lesly I Benitez; Kaijun Di; Hermann B Frieboes; Christopher C W Hughes; Daniela A Bota; John S Lowengrub Journal: Transl Cancer Res Date: 2018-02 Impact factor: 1.241
Authors: Marike L Broekman; Sybren L N Maas; Erik R Abels; Thorsten R Mempel; Anna M Krichevsky; Xandra O Breakefield Journal: Nat Rev Neurol Date: 2018-08 Impact factor: 42.937
Authors: Y Liu; F Li; Y T Yang; X D Xu; J S Chen; T L Chen; H J Chen; Y B Zhu; J Y Lin; Y Li; X M Xie; X L Sun; Y Q Ke Journal: Oncogene Date: 2018-10-27 Impact factor: 9.867
Authors: Marek Z Wojtukiewicz; Marta Mysliwiec; Elwira Matuszewska; Stanislaw Sulkowski; Lech Zimnoch; Barbara Politynska; Anna M Wojtukiewicz; Stephanie C Tucker; Kenneth V Honn Journal: Pathol Oncol Res Date: 2021-03-31 Impact factor: 3.201